ArticleInfection and immunity2020
Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis.
Article in Infection and immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Anti-infective compounds forSustainable microbiology · 2026Review
- Advances in microbial extracellular vesicles: synthetic biology platforms and medical applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Live Plague Vaccine Development: Past, Present, and Future.Vaccines · 2025Review
- Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.Pathogens and disease · 2024Article
- Effects of Yersinia pseudotuberculosis outer membrane vesicles on Pseudomonas aeruginosa antigens immune response.PloS one · 2024Article
- Protective potential of outer membrane vesicles derived from a virulent strain ofFrontiers in microbiology · 2024Article
- Recent Advancements and Novel Approaches Contributing to the Present Arsenal of Prophylaxis and Treatment Strategies Against Category A Bacterial Biothreat Agents.Indian journal of microbiology · 2023Review
- Lung Resident Memory T Cells Activated by Oral Vaccination Afford Comprehensive Protection against Pneumonic Yersinia pestis Infection.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- ModifyingFrontiers in cellular and infection microbiology · 2023Article
- Article
- Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.Advanced drug delivery reviews · 2022Review
- RemodelingProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis.PLoS neglected tropical diseases · 2022Article
- Biological Nanoparticles in Vaccine Development.Frontiers in bioengineering and biotechnology · 2022Review
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
- Article
- Article
- RecombinantInfection and immunity · 2021Article
- Prophylactic vaccine delivery systems against epidemic infectious diseases.Advanced drug delivery reviews · 2021Review
- Engineered Remolding and Application of Bacterial Membrane Vesicles.Frontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.